Publications by authors named "R Ruiz-Villaverde"

368 Publications

Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use.

Dermatol Pract Concept 2021 May 20;11(3):e2021056. Epub 2021 May 20.

Department of Psoriasis, Dermatology, Hospital Universitario San Cecilio, Granada, Spain.

Background: Psoriasis is a chronic inflammatory disease that has a negative impact on patients' quality of life. Patients with mild-moderate psoriasis can be treated with topical medications, such as the combination drug calcipotriol/betamethasone dipropionate (Cal/BD).

Objectives: This study investigated the adherence of psoriasis patients to therapy with Cal/BD aerosol foam, as well as their satisfaction with the treatment's efficacy, safety, and effect on their quality of life.

Methods: Patients with mild-moderate plaque psoriasis were eligible to participate in this open-label, non-placebo controlled, prospective single-center study. Adherence to treatment was assessed using the Morisky-Green scale 4 and 12 weeks after the start of treatment. Satisfaction with the treatment was assessed using the abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9). The severity of psoriasis was assessed on the mIGA and PGA scales, and the impact on quality of life was assessed using the PDI and DLQI scales.

Results: A total of 65 patients entered the study. Adherence to treatment was good, with 73.8% of patients showing high adherence at 12 weeks. Satisfaction was also good, with 46 patients (70.8%) being completely satisfied.

Conclusions: Over a 4-week period, patients treated with Cal/BD aerosol foam had significant improvement in disease severity that was directly related to treatment adherence.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5826/dpc.1103a56DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172017PMC
May 2021

Bullous pemphigoid and COVID-19 vaccine.

Med Clin (Barc) 2021 May 27. Epub 2021 May 27.

Unidad de Gestión Clínica de Dermatología Médico Quirúrgica y Venereología, Hospital Universitario San Cecilio, Granada, España.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.medcli.2021.05.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157120PMC
May 2021

Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study.

Actas Dermosifiliogr 2021 May 27. Epub 2021 May 27.

Vithas Xanit Iinternational Hospital, Benalmádena, Málaga, España.

Background And Objectives: More knowledge about the use of apremilast in real-world settings is needed. The APPRECIATE study (NCT02740218) was designed to describe the characteristics of patients with psoriasis treated with apremilast in routine clinical practice in Spain, evaluate patients' and dermatologists' expectations, and analyze outcomes.

Methods: Retrospective, observational, cross-sectional, multicenter study of patients with chronic plaque psoriasis seen 6 months (plus or minus 1 month) after starting treatment with apremilast. Data were collected from medical records and questionnaires completed by patients and dermatologists.

Results: We studied 80 patients with a mean (SD) Psoriasis Area and Severity Index (PASI) of 8.3 (5.3) and a mean Dermatology Life Quality Index (DLQI) of 8.9 (6.6) at baseline. Forty-seven (58.8%) were still taking apremilast after 6 months (treatment had been discontinued in 16.3% of patients because of a lack of effectiveness and in 20.0% because of safety or tolerability issues). Patients still on treatment at the 6-month visit had a mean DLQI of 2.2 (95% CI, 0.7-3.6) and a mean Patient Benefit Index of 2.8 (0.8); 36.7% had achieved at least a 75% reduction in PASI score (PASI75). Satisfaction of dermatologists' expectations correlated with patients' perception of benefits (r=0.636); 56.3% of patients reported adverse effects (mostly diarrhea and nausea).

Conclusions: Six months of treatment with apremilast in a real-world setting improved the quality of life (mean DLQI reduction > 6 points) of patients with less severe disease than patients in clinical trials.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ad.2021.05.010DOI Listing
May 2021

Nail changes successfully treated with dupilumab in a patient with severe atopic dermatitis.

Australas J Dermatol 2021 May 28. Epub 2021 May 28.

Department of Dermatology, Hospital Universitario San Cecilio, Granada, Spain.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajd.13633DOI Listing
May 2021